Carisma Therapeutics shares are trading higher after the company announced the nomination of the first in vivo CAR-M development candidate for hepatocellular carcinoma under collaboration with Moderna.
Portfolio Pulse from Benzinga Newsdesk
Carisma Therapeutics shares are trading higher after the company announced the nomination of the first in vivo CAR-M development candidate for hepatocellular carcinoma under collaboration with Moderna.
June 28, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Carisma Therapeutics shares are trading higher following the announcement of the first in vivo CAR-M development candidate for hepatocellular carcinoma in collaboration with Moderna.
The announcement of a new development candidate in collaboration with a major player like Moderna is a significant milestone for Carisma Therapeutics. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100